On Friday, October 13, 2023, our Managing Director Ms. Jennifer Che participated as a panelist in InvestHK’s event “Unlock the Life & Health Sciences Potential through Innovation”. Keynote speeches focused on Hong Kong’s strengths in the life sciences (good medical schools, strong research) and also Hong Kong’s challenges bridging the gap between fundamental research and commercial products. The panel discussion centered around “Hong Kong as a life and health technology innovation hub.” Moderated by Dr. Josephine Au from InvestHK, the other panel members included Ir. Eric Chan from Hong Kong Cyberport Management Co. Ltd., Dr. Grace Lau from HKSTP Institute of Translational Research, Ms. Simone Song from ORI Capital and Mr. Henry Yau from HKU Clinical Trials Centre. Jennifer shared about Hong Kong’s uniqueness as a place to find IP experts having international qualifications as well as cross-border experience. She also expressed frustration at how many HK companies still don’t value the importance of good IP strategy (and are unwilling to invest in such matters), which hurts them when they enter the international stage down the road. It was an enlightening discussion and valuable to hear various people’s thoughts on the future of Hong Kong in the life & health sciences area.
我們過去活動
Recommended Insights
China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent
2021年6月9日The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
閱讀更多 >
How a Secondhand Ground Brush Wiped Away a Chinese Patent
2024年12月4日A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor. Highlights Background With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no […]
閱讀更多 >
China Announcing More Proposed Amendments to the Examination Guidelines in 2022
2022年11月17日It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published1, this time consolidating the […]
閱讀更多 >
China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)
2021年4月28日Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]
閱讀更多 >